Evidence map›Paper›PMID 29633110›Full record

ArticleJournal of neuro-oncology2018

Efficacy of intrathecal chemotherapy in patients with central nervous system involvement of hematological malignancies: a retrospective analysis.

A Dara, B B Mook, J K Doorduijn, M J van den Bent, A G Dinmohamed, J E C Bromberg

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

A DaraDepartment of Neurology, Haga Teaching Hospital, Den Haag, The Netherlands. a.dara@rdgg.nl.ORCID http://orcid.org/0000-0002-2258-3302
B B MookDepartment of Neurology, Haga Teaching Hospital, Den Haag, The Netherlands.
J K DoorduijnDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
M J van den BentDepartment of Neuro-oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
A G DinmohamedDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
J E C BrombergDepartment of Neuro-oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Erasmus MC Cancer Institute · NLErasmus MC · NLHaga Hospital · NLReinier de Graaf Hospital · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCentral nervous system (CNS) involvement, especially involvement of the cerebrospinal fluid (CSF), is common in several haematological malignancies. Intrathecal (IT) chemotherapy can be used to manage CSF involvement.

methodsHere we evaluated the effectiveness of IT chemotherapy among 80 patients with haematological malignancies and CSF localization who were treated with IT chemotherapy from 2001 to 2012.

resultsThe majority of patients was diagnosed with diffuse large B-cell lymphoma (26%) or acute lymphoblastic leukaemia/lymphoblastic lymphoma (19%). After first-line IT chemotherapy, which mainly consisted of methotrexate (MTX) and corticosteroids, CSF complete response (CSF CR) was achieved in 76% of patients. 91% reached CSF CR when including second-line IT-chemotherapy. Clinical response was documented in 75%. Although most patients were additionally treated with systemic chemotherapy, response rate did not differ between patients treated with CNS-penetrating and CNS-non-penetrating drugs. CNS progression/relapse occurred in 40% of patients with median progression-free survival of 12.2 months. The median overall survival was 18.3 months; 55% of the patients died during follow-up.

conclusionsOur analysis shows a high response rate after first-line IT chemotherapy, but also a relatively high progression/relapse percentage.

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic AgentsCentral Nervous System NeoplasmsCerebrospinal FluidDisease ProgressionFemaleFollow-Up StudiesHumansInjections, SpinalLeukemiaLymphomaMaleMiddle AgedAntineoplastic AgentsCerebrospinal fluidHematological malignanciesIntrathecal chemotherapyMethotrexate

Identifiers

PMID29633110
OpenAlexW2797674412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.